Trial Profile
A Double-blind, Randomized, Multi-center, Placebo-controlled, Cross-over Study to Assess the Efficacy and Safety of Pancrelipase Delayed Release 24,000 Unit Capsules in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Pancrelipase (Primary)
- Indications Cystic fibrosis; Exocrine pancreatic insufficiency
- Focus Therapeutic Use
- Sponsors Abbott Healthcare Products
- 13 Mar 2018 New trial record
- 20 Jul 2009 Results published in the Trial Registry